Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDX3X | O00571 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 11/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 11/20 | 0.58 |
| ▸ | MAPT | P10636 | 9/20 | 0.58 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | NPC1 | O15118 | 4/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | GFER | P55789 | 1/20 | 0.58 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 4/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8241328 | 0.88 | DDX3X (0.59) | DDX3XMEN1KMT2AMAPTRAB9A | |
| SCHEMBL8238843 | 0.84 | DDX3X (0.68) | DDX3XMEN1KMT2AMAPTNPC1 | |
| SCHEMBL6432678 | 0.79 | MEN1 (0.51) | DDX3XMEN1KMT2AMAPTRAB9A | |
| SCHEMBL14527789 | 0.78 | DDX3X (0.61) | DDX3XMEN1KMT2AMAPTRAB9A | |
| SCHEMBL8231988 | 0.78 | DDX3X (0.61) | DDX3XMEN1KMT2AMAPTRAB9A | |
| SCHEMBL8238479 | 0.77 | MAPT (0.61) | DDX3XMEN1KMT2AMAPTPOLB | |
| SCHEMBL11913667 | 0.76 | DDX3X (1.00) | DDX3XMEN1KMT2AMAPTRAB9A | |
| SCHEMBL12218458 | 0.76 | MAOB (0.60) | MEN1KMT2AMAPTRAB9ANPC1 | |
| SCHEMBL12807606 | 0.73 | KMT2A (0.70) | MEN1KMT2AMAPTRAB9ANPC1 | |
| SCHEMBL15741122 | 0.73 | KMT2A (0.70) | MEN1KMT2AMAPTRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218629-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF DIASTOLIC DYSFUNCTION | Ambetex Pty Ltd (AU) | 2023-07-13 | — | — | US | disclosed |
| US-20230218629-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF DIASTOLIC DYSFUNCTION | Ambetex Pty Ltd (AU) | 2023-07-13 | — | — | US | disclosed |
| EP-1790345-A1 | Triazin beta-secretase inhibitors | Esbatech AG (CH) | 2007-05-30 | — | — | EP | disclosed |
| WO-2007051333-A1 | TRIAZINE BETA-SECRETASE INHIBITORS | ONCALIS AG (CH) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218629-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF DIASTOLIC DYSFUNCTION | TNNI3, TNNT2, TNNC1 | DDX3X 1617/4885MEN1 4032/4885KMT2A 4665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.